<h4>Background</h4>The association between incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and thyroid cancer risk remains controversial. The gene discussed is GLP1R; the disease is thyroid cancer.